Navigation Links
Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy
Date:2/3/2011

LONDON, Feb. 3, 2011 /PRNewswire/ -- Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.  The new investigational regimen, known as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 ('572) and ViiV Healthcare's combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC).

"ViiV Healthcare's goal is to understand and be responsive to the needs of people living with HIV," stated Dominique Limet, Chief Executive Officer, ViiV Healthcare. "With this programme, we are seeking to create an integrase-based, once-daily fixed dose combination that helps meet  patient needs.  We know that even with the successes of current therapies, patients still need additional treatment options and we will continue to evaluate existing and pipeline compounds for new combination therapies."  

"The study of a fixed-dose combination therapy that includes '572 is a signal of Shionogi and ViiV Healthcare's confidence in the compound's potential," said Dr. Sapan Shah, President & CEO, Shionogi Inc. "We're optimistic that '572 will continue to show promise through this research and in the other ongoing Phase III studies that are evaluating it in other HIV treatment regimens."

About the Study: SINGLE (ING114467)The SINGLE study (ING114467) is a multi-centre, multinational, double-blind, two arm study designed to compare the efficacy and safety of 572-Trii ('572 plus ABC/3TC) with that of efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC). This study will include approximately 800 HIV-1 infected treatment-naive patients.

The primary objective for the SINGLE study will be to demonstrate the antiviral activity of 572-Trii once-daily therapy compared to EFV/TDF/FTC over 48 weeks. Secondary objectives include the assessme
'/>"/>

SOURCE Shionogi-ViiV Healthcare, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
4. Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
5. Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
9. Varian, Inc. to Present at Thomas Weisel Partners 2008 Healthcare Conference
10. Thermage, Inc. to Present at the 2008 Thomas Weisel Partners Healthcare Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... of psychiatric disorders has been extremely challenging because there ... are insufficient to cause disease. Now investigators reporting in ... Cell Stem Cell describe a strategy that ... with other risk factors or environmental exposures to affect ... a genetic variant that may predispose individuals to schizophrenia. ...
(Date:7/10/2014)... that power our laptops and electric vehicles could store ... with the help of a sponge-like silicon material. ... graphite traditionally used in one of the battery,s electrodes, ... storage capacity of graphite. A paper describing the material,s ... in Nature Communications . , "Silicon has long ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
(Date:7/10/2014)... will see the two universities and NPL collaborate to ... and industry and their complementary academic strengths., Working with ... shape the scientific priorities of the UK. The establishment ... 300 high-calibre PhD students, will provide a pipeline of ... potential of the Laboratory will be grown through the ...
Breaking Biology Technology:New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... The standard explanation for what causes Alzheimer,s is known ... from of an accumulation of the peptide amyloid beta, the ... the sticky plaques that have defined Alzheimer,s for more than ... spent yearly targeting this toxic peptide but what if ...
... host a conference celebrating the 200th anniversary of ... of Species and the 50th anniversary of the ... Thursday, Oct. 29 to Saturday, Oct. 31. ... History of Science, Darwin/Chicago 2009 will feature presentations ...
... Birmingham (UAB) researchers exploring strategies for conserving the Diamondback ... keep the once-celebrated turtle off the endangered species list. ... a source of state taxes and a casualty of ... its prospects are improved by a UAB-based turtle hatchery ...
Cached Biology News:Rethinking Alzheimer's disease and its treatment targets 2Rethinking Alzheimer's disease and its treatment targets 3UAB research team saves turtle species on the brink 2UAB research team saves turtle species on the brink 3
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... nM is available for in vivo ... in: Z. Hassani, G.-F. Lemkine, P. Erbacher, ... B.-A. Demeneix. Lipid-mediated siRNA delivery down regulates ... at picomolar levels. J. Gene Med., 2005, ...
... transfection reagent that achieves over 90 % ... a wide variety of adherent and primary ... siRNA concentrations avoids unwanted toxic and off-target ... higher concentrations, thereby allowing accurate and reliable ...
... Immunoperoxidase Secondary Detection System uses biotin-avidin-HRP complexed ... in the Primary Antibody. The primary antibody ... specimen. Any excess antibody is removed by ... to biotin) is added and will react ...
Biology Products: